Design: cluster-randomised trial across ten centres (BRIDGE)
Population: 329 patients with acute coronary syndrome; mean age 69 years, 18% women, median baseline LDL-C 110 mg/dL
Primary outcome: achievement of LDL-C below 70 mg/dL at 6 months
Effect: 86.4% vs 73.7% (difference 12.6 percentage points; 95% CI 3.8-21.5; P = 0.005); LDL-C below 55 mg/dL 60.8% vs 34.5% (difference 26.3 points; 95% CI 18.5-34.0)

BRIDGE cluster-randomised ten centres to protocol-based or standard lipid management after acute coronary syndrome. In the protocol arm, lipid-lowering therapy was started or intensified during the index admission according to a prespecified algorithm using high-intensity statins, ezetimibe and PCSK9 inhibitors, with LDL-C rechecked at four weeks and escalated when it was above about 55 mg/dL.

At six months, 86.4% of the protocol group had LDL-C below 70 mg/dL against 73.7% under standard care, a difference of 12.6 percentage points. The gap widened at the stricter target: 60.8% versus 34.5% below 55 mg/dL, a difference of 26.3 percentage points. Median LDL-C at baseline was 110 mg/dL, so both arms moved substantially — the protocol simply moved further.

Nothing here is a new drug or a new target. The intervention is an algorithm written down, applied before discharge, with a scheduled recheck. That is the whole content, and it produced a difference of the size usually sought from a new agent.

This is the most transferable finding in today's edition. A unit can write the algorithm this week, and the recheck at four weeks is the piece most often missing — intensification that waits for the three-month clinic visit is intensification that frequently never happens.

Write the post-ACS lipid algorithm down and attach it to the discharge process, rather than leaving intensity to the discharging doctor
Start or intensify therapy during the index admission, not at the follow-up visit
Book the four-week lipid recheck before the patient leaves the ward
Use an operational threshold below the guideline goal — the protocol escalated at about 55 mg/dL to reliably land under 70
Audit the proportion of your own ACS discharges achieving LDL-C under 70 mg/dL at six months; that number is the outcome this trial improved

Don't overread it

The endpoint was LDL-C achievement at six months, not cardiovascular events — the outcome benefit is inferred from the established relationship between LDL-C and risk.

The statistics, in plain English

The primary result, a 12.6 percentage point difference with a 95% confidence interval of 3.8 to 21.5, is significant at the patient level. But a hospital-level sensitivity analysis — the more conservative way to analyse a cluster-randomised trial, because patients within a centre are not independent of each other — gave 12.8 percentage points with an interval of -2.0 to 27.6, which crosses zero. With only ten centres, that analysis has very little power, so the honest reading is that the effect is real but its size is less certain than the headline interval suggests. The endpoint is also a surrogate: LDL-C achievement, not events.